|
September 28, 2010
Tesamorelin Growth Hormone-releasing Factor Reduces Visceral Fat in Diverse Patient Groups
HIVandHepatitis.com: "SUMMARY: Tesamorelin (TH9507, brand name Egrifta), a recombinant form of human growth hormone-releasing factor, decreased the amount of visceral abdominal fat over 1 year in a variety of sub-populations of HIV patients with lipodystrophy, according to research presented at the recent 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). A related study found that fat loss measured by CT scans was reflected in reduced waist size and improved patient-reported body image."
Subscribe to:
Post Comments (Atom)
2 comments:
Does anyone know when this will actually come to market in the US?
The company is expecting to receive the approval any days. If approved before mid November 2010, Egrifta (tesamorelin) could be available before the end of this year.
Post a Comment